Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.47 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2094874 | 0.87 | NFE2L2 (0.47) | SMN1; SMN2SRCTLR2ERN1TLR1 | |
| SCHEMBL11039664 | 0.86 | SRC (0.61) | SRCTLR2ERN1TLR1TLR6 | |
| SCHEMBL27872668 | 0.86 | SRC (0.39) | SMN1; SMN2SRCTLR2ERN1TLR1 | |
| Formic Acid Methyl Ester SCHEMBL28069288 | 0.82 | NFE2L2 (0.50) | SMN1; SMN2SRCTLR2ERN1TLR1 | |
| SCHEMBL28090574 | 0.80 | SRC (0.38) | SMN1; SMN2SRCTLR2ERN1TLR1 | |
| SCHEMBL97371 | 0.79 | CA1 (0.62) | SMN1; SMN2TLR2ERN1TLR1TLR6 | |
| SCHEMBL14579653 | 0.78 | TLR2 (0.44) | TLR2ERN1TLR1TLR6CA12 | |
| SCHEMBL28875099 | 0.78 | ALDH1A1 (0.46) | SMN1; SMN2SRCNFE2L2KDM4ELMNA | |
| SCHEMBL28158293 | 0.78 | TUBB4A (0.47) | SRCTLR2ERN1TLR1TLR6 | |
| SCHEMBL28866717 | 0.78 | SRC (0.39) | SMN1; SMN2SRCTLR2ERN1TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022272094-A1 | RECOVERY OF MONOMERIC AND OLIGOMERIC BUILDING BLOCKS FROM POLYMERIC MATERIALS | ALIGN TECHNOLOGY, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20120209007-A9 | TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-08-16 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20110319629-A1 | TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-12-29 | — | — | US | disclosed |
| EP-2396289-A1 | TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES | Agency For Science, Technology And Research (SG) | 2011-12-21 | — | — | EP | disclosed |
| US-20100249443-A1 | TITANIUM COMPOUND AND PROCESS FOR ASYMMETRIC CYANATION OF IMINES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-09-30 | — | — | US | disclosed |
| WO-2010093336-A1 | TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010093327-A1 | TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-08-19 | — | — | WO | disclosed |
| WO-2008121074-A1 | METHOD OF PRODUCING AN OPTICALLY ACTIVE CYANOHYDRIN DERIVATIVE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2008-10-09 | — | — | WO | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20070265463-A1 | Titanium Compound and Process for Producing Optically Active Cyanohydrins | MITSUI CHEMICALS, INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1806336-A1 | TITANIUM COMPOUND AND METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRINS | Mitsui Chemicals, Inc. (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SMN1; SMN2 3985/4885SRC 4684/4885TLR2 238/4885 |
| US-20070265463-A1 | Titanium Compound and Process for Producing Optically Active Cyanohydrins | WNT1, C3AR1, TDO2 | SMN1; SMN2 4727/4885SRC 1577/4885TLR2 1603/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | SMN1; SMN2 3787/4885SRC 4843/4885TLR2 112/4885 |
| US-20110319629-A1 | TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES | ABL1, TYR, CD59 | SMN1; SMN2 3695/4885SRC 98/4885TLR2 658/4885 |
| US-20100249443-A1 | TITANIUM COMPOUND AND PROCESS FOR ASYMMETRIC CYANATION OF IMINES | ABL1, CD59, TDO2 | SMN1; SMN2 3839/4885SRC 191/4885TLR2 893/4885 |
| US-20120209007-A9 | TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES | ABL1, TYR, CD59 | SMN1; SMN2 3695/4885SRC 98/4885TLR2 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.